Australia is closely watching the arrival of retatrutide, a cutting-edge dual GIP and GLP-1 receptor agonist , representing a significant advance in obesity treatment . Early clinical trials have demonstrated https://giant-bikes-cypress329889.law-wiki.com/2728826/emerging_medication_in_australia_a_promising_solution_for_reducing_body_weight